木瓜直播

Older adults treated for cancer had double the risk of , including stroke, as compared with those without cancer, emphasizing the need for long-term monitoring after cancer treatment. (Cancer)

The isatuximab (Sarclisa), in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, for newly diagnosed, transplant-ineligible multiple myeloma.

Will peptide-drug conjugates in targeted cancer therapy? (Endpoints News)

Bristol Myers Squibb and 2seventy bio announced in the phase III KarMMa-9 trial of idecabtagene vicleucel (Abecma) and lenalidomide in newly diagnosed multiple myeloma with suboptimal response to transplant because of slow patient accrual.

A phase III trial of the fixed-dose combination of the LAG-3 inhibitor favezelimab and pembrolizumab (Keytruda) of overall survival in previously treated, PD-L1-positive, microsatellite stable metastatic colorectal cancer, Merck announced.

Lehigh Valley Health Network in Pennsylvania agreed to pay $65 million to settle a lawsuit after computer hackers posted online. (CNN)

Adding ruxolitinib (Jakafi) to standard tyrosine kinase therapy for significantly increased the frequency of deep molecular response. (SWOG)

AstraZeneca and Daiichi Sankyo announced that the antibody-drug conjugate datopotamab deruxtecan in a phase III trial of inoperable/metastatic hormone receptor-positive, HER2-low or HER2-negative breast cancer previously treated with endocrine therapy.

New HHS rules on still do not address the root cause of the problem -- the "publish-or-perish" mentality, an opinion piece argues. (STAT)

Black patients with may be less likely to receive immunotherapy, despite having outcomes similar to those of white patients when they do. (American Association for Cancer Research)

Comment